VISION vol.24
【VISION 最新・血液内科シリーズvol.24 私と仲間たち】




  1. Empirical versus Preemptive Antifungal Therapy for High-Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial.Clinical Infectious Diseases 2009; 48:1042–51.
  2. Universal antifungal therapy is not needed in persistent febrile neutropenia:
    a tailored diagnostic and therapeutic approach.Haematologica 2012;97(3):464-471.


  1. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis.N Engl J Med 2012;366:787-98.
  2. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis.N Engl J Med 2012;366:799-807.



  1. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood. 2011;117(3):936-941.



  1. Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. J Clin Oncol. 2010;28:5101-5109.
  2. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan- prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood.2011;118(22):5759-5766.


  1. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. Journal of Hematology & Oncology . 2011 . 4:46.


  1. A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR. Biol Blood Marrow Transplant . 2010;16:35-45.
  2. Hematopoietic Cell Transplantation for Lymphomas.  Cancer Control. 2011;18(4):246-257.
  3. Survial Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin's Lymphoma: Final Annalysis of the Prospective LNH87-2 Protocol-A Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol . 2000;18:3025-3030.
  4. Autologous Bone Marrow Translantation as Compared With Salvage Chemotherapy In Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma. N Engl J Med . 1995;333:1540-1545.

  1. Horse versus Rabbit Antithymocyte Goldulin in Acquired Aplastic Anemia.N Engl J. 2011;365:430-438.


  1. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both
    bortezomib and lenalidomide: comparison of 2 dosing strategies in
    dual-refractory disease.Blood. 2011;118(11):2970-2975.
  2. Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma.J Clin Oncol.2009;27:5008-5014.
  3. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).Leukemia. 2010
    ; 24(11): 1934–1939.


  1. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation.Blood. 2006;107:3034-3044.



  1. Recommendations for the Use of Antiemetics:Evidence-Based, Clinical Practice Guidelines.Journal of Clinical Oncology,1999;17:2971-2994.
  2. American Society of Clinical Oncology Guideline for Antiemetics in Oncology:Update 2006.Journal of Clinical Oncology,2006;24:2932-2947.
  3. The Role of Neurokinin-1 Antagonists in the Prevention of Emesis due to Hihg-dose Cisplatin : A Systematic Review.

  1. Modern Strategies for Hairy Cell Leukemia.J Clin Oncol.2011;29:583-590.
  2. Primary Autoimmune Myelofibrosis:Definition of a Distinct Clinicopathologic Syndrome.American Journal of Hematology.2003;72:8-12.

  1. TET Genes: new players in DNA demethylation and important determinants for stemness.Experimental Hematology press.
  2. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.Nature .2010;468, 839–843.
  3. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.Leukemia .2011. 1–6.

(研修医) 発表
  1. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood.2004;103:1527-1533.

6月2日(木)川島一郎 発表
  1. aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLfor the treatment of young patients with good-prognosis (normal LDH) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide.Blood. 2004;104:626-633.
  2. lymphoma treated with R-CHOPoutcome than the standard IPI for patients with diffuse large B-cell The revised International Prognostic Index (R-IPI) is a better predictor of.Blood. 2007;109:1857-1861.
  3. Non-Hodgkin Lymphoma Study Group (DSHNHL)of patients treated in the RICOVER-60 trial of the German High-Grade modern chemotherapy (CHOP-14) with or without rituximab: an analysis CNS events in elderly patients with aggressive lymphoma treated with.Blood. 2009;113:3896-3902.
  4. How I treat elderly patients with diffuse large B-cell lymphoma .Blood. 2010;116(24):5103-5110.
  5. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) .Lancet Oncol 2008; 9:(105)8211;16.


5月26日(木)山口千之(研修医) 発表

  1. Cytarabine Dose for Acute Myeloid Leukemia.N Engl J Med. 2011;364:1027-1036.
  2. A Randomized Study of High-Dose Cytarabine in Induction in Acute Myeloid Leukemia.Blood. 1996 87: 1710-1717.
  3. A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.Blood.2005;105:481-488.

5月19日(木)山本健夫 発表

  1. How I treat elderly patients with myeloma.Blood. 2010;116(13):2215-2223.
  2. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.Am. J. Hematol. 2011;86:18–24.
  3. MyelomaAge Is Not a Prognostic Variable With Autotransplants for Multiple.Blood, 1999;93(1): 51-54.

5月12日(木)小林武文、落合頼業、輿石めぐみ(医学科6年生 発表

  1. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.Blood.2011;117(16):4190-4207.
  2. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.Lancet 2009; 373: 1562–1569.



4月21日(木)野崎由美 発表
  1. How I treat mantle cell lymphoma.Blood. 2009;114:1469-1476.
  2. Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma.J Clin Oncol.2008; 26:4473-4479.
  3. Novel therapeutic agents for B-cell lymphoma: developing rational combinations.Blood.2011;117(5):1453-1462.
  4. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.Blood. 2008;111:558-565.
  5.  Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma.J Clin Oncol.2005;23:5347-5356.

4月14日(木)中嶌圭 発表

  1. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.Nature GeNetics.2010;42:722-727.
  2. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β.Molecular Cancer.2010;9:1-12.
  3. Polycomb proteins in hematologic malignancies.Blood.2010;116(25):5465-5475.